Pharmaceutical

EC approves Astellas’ PADCEV for urothelial cancer

The European Commission has authorised Astellas Pharma's PADCEV regimen for the first-line treatment of advanced urothelial cancer.

Aug 29, 2024 - 04:00
EC approves Astellas’ PADCEV for urothelial cancer
The European Commission has authorised Astellas Pharma's PADCEV regimen for the first-line treatment of advanced urothelial cancer.
Read the original article

Tags:

Previous Article

Navigator gains $100m in Series A funding for antibody therapeutics

Next Article

Pfizer launches digital healthcare platform to streamline access

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

King Charles’ diagnosis raises awareness on prostate condition 

King Charles’ diagnosis raises awareness on prostate co...

Jan 29, 2024

A psychologist’s lifetime of challenging assumptions while living with paralysis

A psychologist’s lifetime of challenging assumptions wh...

Jul 26, 2023

Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Ipilimumab by Bristol-Myers Squibb for Metastatic Trans...

Aug 30, 2023